Mural Oncology plc (MURA)
$2.04+0.00%Close
SELLBEAR · day 9
Key stats
- Market cap
- $35M
- Beta
- 2.96
- P/E (TTM)
- -0.68
- 1W
- +0.49%
- 1M
- -2.39%
- vs SPY 1W
- +0.07%
- vs SPY 1M
- -4.45%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 16
- VALUE
- 20
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-54.4%
REV YoY-
ROE-90.7%
EPS YoY-
ROA-78.6%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.68
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.64
P/FCF-
EV/EBITDA0.40
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E6.43
ALTMAN Z-
CURR RATIO5.90
ND/EBITDA-
BETA2.96
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on MURA?
- LOPJLB’s latest quantitative signal on Mural Oncology plc (MURA) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is MURA in?
- Mural Oncology plc (MURA) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Mural Oncology plc (MURA) do?
- Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer. Its primary drug candidate, nemvaleukin alfa, is currently under investigation as a standalone agent for mucosal melanoma and in partnership with pembrolizumab for platinum-resistant ovarian cancer. Additionally, the company is progressing projects cent…